<DOC>
	<DOC>NCT01061177</DOC>
	<brief_summary>This study will assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. The aim of the study is to confirm the rates of complete molecular remission (CMR) of nilotinib in newly diagnosed CML chronic phase patients in a pan-European population using the EUTOS standardized laboratories.</brief_summary>
	<brief_title>Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome &amp; /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Patients with diagnosis of CPCML with cytogenetic confirmation of Philadelphia (Ph) chromosome Ph negative cases or patients with variant translocations who are BCRABL positive in multiplex PCR are also eligible WHO performance status 02 Laboratory assessments within normal limits Written informed consent prior to any study procedures being performed Known impaired cardiac function History of acute or chronic pancreatitis Impaired gastrointestinal function or disease that may alter the absorption of study drug Concomitant medications with potential QT prolongation, or known to interact with CYP450 isoenzymes (CYP3A4, CYP2C9, and CYP2C8) Patients who have undergone major surgery â‰¤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy Patients who are pregnant or breast feeding, or females of reproductive potential not employing an effective method of birth control. Female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>myeloid</keyword>
	<keyword>myelogenous</keyword>
	<keyword>chronic BCR-ABL positive</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>CML in chronic phase</keyword>
</DOC>